Study population divided according to threshold determined ROC analysis, 24 hours after STEMI
| Variable . | H3Cit-DNA >219.3 μg/L (n = 81) . | H3Cit-DNA ≤219.3 μg/L (n = 280) . | P value . |
|---|---|---|---|
| Characteristics | |||
| Age, y | 66 ± 13 | 63 ± 12 | .156 |
| Sex, n (%) | |||
| Female | 17 (21) | 64 (23) | .756 |
| Male | 64 (79) | 216 (77) | .765 |
| BMI, kg/m2 | 26.9 ± 3.6 | 27.0 ± 4.4 | .807 |
| Disorders, n (%) | |||
| Arterial hypertension | 51 (63) | 179 (64) | .896 |
| Diabetes mellitus | 37 (46) | 108 (39) | .303 |
| Hyperlipidaemia | 24 (30) | 97 (35) | .426 |
| Smoker | 37 (46) | 157 (56) | .102 |
| Previous MI | 6 (7) | 32 (11) | .411 |
| Known CAD/previous PCI | 25 (31) | 81 (29) | .782 |
| Infarct characteristics | |||
| Number of diseased vessel | |||
| 1-vessel disease, n (%) | 17 (21) | 58 (21) | 1.000 |
| 2-vessel disease, n (%) | 13 (16) | 58 (21) | .440 |
| 3-vessel disease, n (%) | 51 (63) | 164 (59) | .561 |
| Blood parameter | |||
| Total cholesterol, mg/dL | 133.62 ± 38.81 | 146.35 ± 36.32 | .046 |
| TG, mg/dL | 135.95 ± 61.01 | 136.47 ± 64.19 | .662 |
| HDL, mg/dL | 35.65 ± 9.92 | 38.87 ± 11.94 | .116 |
| LDL, mg/dL | 76.08 ± 30.92 | 86.85 ± 32.67 | .061 |
| Lp(a), mg/dL | 49.26 ± 60.78 | 55.36 ± 65.62 | .663 |
| GFR, mL/min | 65.07 ± 28.44 | 76.57 ± 22.88 | .002 |
| HbA1c, % | 6.15 ± 1.25 | 6.14 ± 1.34 | .899 |
| CRP, mg/L | 7.75 ± 8.33 | 4.20 ± 6.37 | <.001 |
| TnT, mg/L | 3581.99 ± 4542.52 | 2390.72 ± 4022.34 | .009 |
| CK, U/L | 658.19 ± 1271.45 | 483.10 ±2265.43 | .052 |
| Preexisting antiplatelet therapy | 21 (26) | 98 (35) | .141 |
| Aspirin | 20 (25) | 90 (32) | .219 |
| P2Y12 inhibitor | 5 (6) | 24 (9) | .644 |
| Variable . | H3Cit-DNA >219.3 μg/L (n = 81) . | H3Cit-DNA ≤219.3 μg/L (n = 280) . | P value . |
|---|---|---|---|
| Characteristics | |||
| Age, y | 66 ± 13 | 63 ± 12 | .156 |
| Sex, n (%) | |||
| Female | 17 (21) | 64 (23) | .756 |
| Male | 64 (79) | 216 (77) | .765 |
| BMI, kg/m2 | 26.9 ± 3.6 | 27.0 ± 4.4 | .807 |
| Disorders, n (%) | |||
| Arterial hypertension | 51 (63) | 179 (64) | .896 |
| Diabetes mellitus | 37 (46) | 108 (39) | .303 |
| Hyperlipidaemia | 24 (30) | 97 (35) | .426 |
| Smoker | 37 (46) | 157 (56) | .102 |
| Previous MI | 6 (7) | 32 (11) | .411 |
| Known CAD/previous PCI | 25 (31) | 81 (29) | .782 |
| Infarct characteristics | |||
| Number of diseased vessel | |||
| 1-vessel disease, n (%) | 17 (21) | 58 (21) | 1.000 |
| 2-vessel disease, n (%) | 13 (16) | 58 (21) | .440 |
| 3-vessel disease, n (%) | 51 (63) | 164 (59) | .561 |
| Blood parameter | |||
| Total cholesterol, mg/dL | 133.62 ± 38.81 | 146.35 ± 36.32 | .046 |
| TG, mg/dL | 135.95 ± 61.01 | 136.47 ± 64.19 | .662 |
| HDL, mg/dL | 35.65 ± 9.92 | 38.87 ± 11.94 | .116 |
| LDL, mg/dL | 76.08 ± 30.92 | 86.85 ± 32.67 | .061 |
| Lp(a), mg/dL | 49.26 ± 60.78 | 55.36 ± 65.62 | .663 |
| GFR, mL/min | 65.07 ± 28.44 | 76.57 ± 22.88 | .002 |
| HbA1c, % | 6.15 ± 1.25 | 6.14 ± 1.34 | .899 |
| CRP, mg/L | 7.75 ± 8.33 | 4.20 ± 6.37 | <.001 |
| TnT, mg/L | 3581.99 ± 4542.52 | 2390.72 ± 4022.34 | .009 |
| CK, U/L | 658.19 ± 1271.45 | 483.10 ±2265.43 | .052 |
| Preexisting antiplatelet therapy | 21 (26) | 98 (35) | .141 |
| Aspirin | 20 (25) | 90 (32) | .219 |
| P2Y12 inhibitor | 5 (6) | 24 (9) | .644 |
Data are presented as mean ± standard deviation or number (percent) of patients.
Abbreviations are explained in Table 1. Boldface indicates P values were considered significant if P < 0.05.